ARDX News and Press, Ardelyx Inc. From 03/08/22

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

3 Penny Stocks to Add to Your Watchlist as the Market Drops If you’re looking for penny stocks to buy, there are hundreds of options to choose from. But, because of the sheer number of penny stocks out there, knowing how to separate the good from the bad is crucial. This can ...

3 Penny Stocks to Add to Your Watchlist Right Now As we continue to traverse through trading penny stocks in March 2022, there is a lot for investors to consider. Of course, the largest factor at play right now is the invasion of Ukraine by Russia. While this has caused major downtrends...

Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference PR Newswire WALTHAM, Mass. , March 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative fi...

Everyone wants a deal in the stock market today, and that means finding things on the cheap. No other asset class has met this simple framework other than penny stocks. We’re talking about stocks under $5 by definition, and their rampant volatility has resulted in some of the most si...

Micro-cap biotech Ardelyx (NASDAQ:ARDX) is trading ~11% higher in the pre-market on Wednesday after Jefferies analyst Christopher Howerton upgraded the stock to Buy from Hold citing its valuation. Ardelyx (ARDX) has lost more than 89% over the past 12 months, and Howerton cites its ...

Ardelyx, Inc. (ARDX) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Justin Renz - CFO Mike Raab - President & CEO Susan Rodriguez - Chief Commercial Officer Robert Blanks - Chief Regulatory Affairs & Quality Assurance Officer Conference Call Partici...

Ardelyx press release (NASDAQ:ARDX): Q4 GAAP EPS of -$0.31 misses by $0.05. Revenue of $1.03M (-44.4% Y/Y) beats by $0.12M. For further details see: Ardelyx GAAP EPS of -$0.31 misses by $0.05, revenue of $1M beats by $0.12M

Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights Company Advancing Toward Launch of IBSRELA® in April 2022 Conference Call scheduled for 4:30 PM Eastern Time PR Newswire WALTHAM, Mass. , Feb. 28, 2022 /PRNewsw...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...